Natural products are a vast source of potential compounds that can be developed as anti-obesity agent. One of the mechanisms of anti-obesity agents is inhibition of pancreatic lipase. Assay of 24 crude extracts for their in vitro activity against porcine pancreatic lipase (PPL) detected four extracts demonstrating high (>70%) inhibition, seven extracts had medium (30-70%) inhibition and the remaining 13 extracts exhibited low (<30%) inhibition when incubated with PPL at a concentration of 500 µg/ml for 10 min at 37°C. Phyllanthus niruriextract displayed the most potent PPL inhibitor, followed by Orthosiphon stamineus, Murraya paniculata andAverrhoa bilimbi with the IC50 value of 27.7<34.7< 41.5<55.2 µg/ml, respectively. P. niruri &O. stamineus (the best two extracts) showed noncompetitive and uncompetitive inhibition, respectively. P. niruri &O. stamineus displayed total phenolic content of 431.0 ± 0.01 and 103.0 ± 0.01 mg GAE/g dry extract, while total flavonoid content of 14.8 ± 0.07 and 21.6 ± 0.03 mg QE/g dry extract, respectively. Both P. niruri &O. stamineus extracts showed high antioxidant activity, with EC50 values of 8.4 and 26.3 µg/ml, respectively. The results suggest that P. niruri &O. stamineus may be beneficial for obesity treatment via pancreatic lipase inhibition action.
No takes yet. Share an insight, caveat, or question.
Raja Noor Zaliha Raja Abd Rahman (2017) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: